Amundi Purchases 327,688 Shares of Kenvue Inc. (NYSE:KVUE)

Amundi raised its position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 4.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,506,253 shares of the company's stock after buying an additional 327,688 shares during the quarter. Amundi owned about 0.39% of Kenvue worth $158,577,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Huntington National Bank raised its position in shares of Kenvue by 26.5% in the 3rd quarter. Huntington National Bank now owns 4,161 shares of the company's stock worth $96,000 after purchasing an additional 871 shares during the last quarter. ING Groep NV raised its position in shares of Kenvue by 23.6% in the 3rd quarter. ING Groep NV now owns 3,576,616 shares of the company's stock worth $82,727,000 after purchasing an additional 681,954 shares during the last quarter. Handelsbanken Fonder AB raised its position in shares of Kenvue by 2.9% in the 4th quarter. Handelsbanken Fonder AB now owns 742,184 shares of the company's stock worth $15,846,000 after purchasing an additional 21,222 shares during the last quarter. Alberta Investment Management Corp raised its position in shares of Kenvue by 23.2% in the 4th quarter. Alberta Investment Management Corp now owns 582,895 shares of the company's stock worth $12,445,000 after purchasing an additional 109,700 shares during the last quarter. Finally, Longbow Finance SA raised its position in shares of Kenvue by 5.0% in the 4th quarter. Longbow Finance SA now owns 280,568 shares of the company's stock worth $5,990,000 after purchasing an additional 13,287 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $24.00 price target on shares of Kenvue in a research report on Monday, February 3rd. Barclays lowered their price target on Kenvue from $23.00 to $21.00 and set an "equal weight" rating for the company in a research report on Friday, January 17th. Deutsche Bank Aktiengesellschaft downgraded Kenvue from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $25.00 to $24.00 in a report on Thursday, December 12th. Piper Sandler lifted their price objective on Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a report on Monday, February 24th. Finally, Canaccord Genuity Group lifted their price objective on Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $23.75.

Kenvue Stock Performance

Shares of NYSE:KVUE traded up $0.48 during midday trading on Monday, hitting $23.90. The company had a trading volume of 18,034,740 shares, compared to its average volume of 14,630,980. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46. The company has a fifty day moving average of $21.64 and a two-hundred day moving average of $22.33. The company has a market cap of $45.67 billion, a price-to-earnings ratio of 45.09, a PEG ratio of 2.62 and a beta of 1.25. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, equities research analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were issued a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a yield of 3.43%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue's dividend payout ratio is currently 154.72%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.